Sildenafil for pulmonary arterial hypertension: When blue turns into white

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1801-1810

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Phosphodiesterase 5 inhibitors; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE;

ANIMAL; CHEMISTRY; COLOR; HUMAN; METABOLISM; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; COLOR; CYCLIC GMP; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PIPERAZINES; PURINES; SULFONES;

EID: 35548948224     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1801     Document Type: Review

References (81)

1. RUBIN LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):4S-6S. •• Updated guidelines on PAH diagnosis and management.
2. SIMONNEAU G, GALIE N, RUBIN LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):5S-12S. •• The most recent clinical classification of pulmonary hypertension.
3. D'ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. (1991) 115(5):343-349. • Seminal study on PPH survival.
4. BARST RJ, MCGOON M, TORBICKI A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):40S-47S. •• Updated guidelines on PAH diagnosis and management.
5. MCGOON M, GUTTERMAN D, STEEN V et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):14S-34S. (Pubitemid 38932340)
6. GALIE N, TORBICKI A, BARST R et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. (2004) 25(24):2243-2278. •• Updated guidelines on PAH diagnosis and management.
7. HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436. • Paper highlighting the specific therapies.
8. CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):70-75.
9. GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1995) 333(4):214-221.
10. GIAID A, YANAGISAWA M, LANGLEBEN D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1993) 328(24):1732-1739. (Pubitemid 23170122)
11. RUNO JR, LOYD JE: Primary pulmonary hypertension. Lancet (2003) 361(9368):1533-1544. (Pubitemid 36566349)
12. PROVENCHER S, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin. Pharmacother. (2005) 6(8):1337-1348. •• Review on the use of bosentant for PAH treatment.
13. BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):35S-62S. •• Updated guidelines on PAH diagnosis and management. (Pubitemid 38932341)
14. RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):76-81.
15. SITBON O, HUMBERT M, JAIS X et al.: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 111(23):3105-3111. (Pubitemid 40847788)
16. FUSTER V, STEELE PM, EDWARDS WD et al.: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 70(4):580-587. (Pubitemid 14020655)
17. OGATA M, OHE M, SHIRATO K, TAKISHIMA T: Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn. Circ. J. (1993) 57(1):63-69. (Pubitemid 23071864)
18. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann. Intern. Med. (1980) 93(3):391-398.
19. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet (1981) 1(8222):681-686.
20. RICH S, SEIDLITZ M, DODIN E et al.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest (1998) 114(3):787-792. (Pubitemid 28433741)
21. TUDER RM, COOL CD, GERACI MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159(6):1925-1932. (Pubitemid 29275065)
22. BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. (2000) 132(6):425-434. (Pubitemid 30149039)
23. BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302. • Study assessing the safety and efficacy of epoprostenol for PAH treatment.
24. BARST RJ, RUBIN LJ, MCGOON MD et al.: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121(6):409-415. • Study assessing the impact of epoprostenol therapy on PPH survival.
25. MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. (1998) 338(5):273-277. (Pubitemid 28065252)
26. SHAPIRO SM, OUDIZ RJ, CAO T et al.: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J. Am. Coll. Cardiol. (1997) 30(2):343-349. (Pubitemid 27339311)
27. SITBON O, HUMBERT M, NUNES H et al.: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. (2002) 40(4):780-788. • Study assessing the impact of epoprostenol therapy on PPH survival.
28. BARST RJ, MCGOON M, MCLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(12):2119-2125. (Pubitemid 36724255)
29. HOEPER MM, SCHWARZE M, EHLERDING S et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. (2000) 342(25):1866-1870. (Pubitemid 30419050)
30. OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347(5):322-329. (Pubitemid 34815354)
31. OPITZ CF, WENSEL R, WINKLER J et al.: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. (2005) 26(18):1895-1902. • Sudy evaluating therapeutic outcomes of inhaled iloprost in IPAH.
32. SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804. (Pubitemid 34229650)
33. RUBENS C, EWERT R, HALANK M et al.: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest (2001) 120(5):1562-1569. (Pubitemid 33078473)
34. HAYNES WG, WEBB DJ: Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. (1998) 16(8):1081-1098. (Pubitemid 28334007)
35. MCLAUGHLIN VV, SITBON O, BADESCH DB et al.: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. (2005) 25(2):244-249. • Study assessing the impact of first-line bosentan therapy on PPH survival.
36. GALIE N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46(3):529-535. (Pubitemid 41040298)
37. BARST RJ, RICH S, WIDLITZ A et al.: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 121(6):1860-1868. (Pubitemid 34634407)
38. DUNKERN TR, HATZELMANN A: The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell. Signal. (2005) 17(3):331-339. (Pubitemid 39574694)
39. WHARTON J, STRANGE JW, MOLLER GM et al.: Antiproliferative effects of phosphodiesterase Type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. (2005) 172(1):105-113. (Pubitemid 40923321)
40. MICHELAKIS ED: The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. (2003) 8(1):5-21. (Pubitemid 36342286)
41. LADHA F, BONNET S, EATON F et al.: Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med. (2005) 172(6):750-756. (Pubitemid 41324231)
42. TANTINI B, MANES A, FIUMANA E et al.: Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res. Cardiol. (2005) 100(2):131-138. (Pubitemid 40361605)
43. TURKO IV, BALLARD SA, FRANCIS SH, CORBIN JD: Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol. Pharmacol. (1999) 56(1):124-130. (Pubitemid 29309820)
44. KLINGER JR, THAKER S, HOUTCHENS J et al.: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest (2006) 129(2):417-425. (Pubitemid 43289864)
45. PRESTON IR, HILL NS, GAMBARDELLA LS, WARBURTON RR, KLINGER JR: Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Experimental Biology and Medicine (2004) 229(9):920-925. (Pubitemid 39539377)
46. ZHAO L, MASON NA, STRANGE JW, WALKER H, WILKINS MR: Beneficial Effects of Phosphodiesterase 5 Inhibition in Pulmonary Hypertension Are Influenced by Natriuretic Peptide Activity. Circulation (2003) 107(2):234-237. (Pubitemid 36135217)
47. PAUL GA, GIBBS JSR, BOOBIS AR, ABBAS A, WILKINS MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. (2005) 60(1):107-112. (Pubitemid 40942789)
48. CHEITLIN MD, HUTTER AM Jr, BRINDIS RG et al.: Use of sildenafil (viagra) in patients with cardiovascular disease. Circulation (1999) 99(1):168-177. (Pubitemid 29035976)
49. GILLIES HC, ROBLIN D, JACKSON G: Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int. J. Cardiol. (2002) 86(2-3):131-141. (Pubitemid 35284801)
50. ZHAO L, MASON NA, MORRELL NW et al.: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation (2001) 104(4):424-428. (Pubitemid 32678272)
51. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44(7):1488-1496. • Haemodynamic study on phosphodiesterase-5 inhibitors.
52. GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. (2002) 136(7):515-522. (Pubitemid 34252285)
53. GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 360(9337):895-900. (Pubitemid 35283832)
54. KUHN KP, WICKERSHAM NE, ROBBINS IM, BYRNE DW: Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp. Lung Res. (2004) 30(2):135-145. (Pubitemid 38293714)
55. LEPORE JJ, MAROO A, BIGATELLO LM et al.: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest (2005) 127(5):1647-1653. (Pubitemid 46218790)
56. LEUCHTE HH, SCHWAIBLMAIR M, BAUMGARTNER RA et al.: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest (2004) 125(2):580-586. (Pubitemid 38223639)
57. MICHELAKIS E, TYMCHAK W, LIEN D et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105(20):2398-2403. (Pubitemid 34556392)
58. WILKENS H, GUTH A, KONIG J et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 104(11):1218-1222. (Pubitemid 32848108)
59. CHOCKALINGAM A, GNANAVELU G, VENKATESAN S et al.: Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int. J. Cardiol. (2005) 99(1):91-95. (Pubitemid 40261030)
60. SHETH A, PARK JE, ONG YE, HO TB, MADDEN BP: Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul. Pharmacol. (2005) 42(2):41-45. (Pubitemid 40259714)
61. BHARANI A, MATHEW V, SAHU A, LUNIA B: The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. (2003) 55(1):55-59. • Tolerability and efficacy study with sildenafil in patients with pulmonary hypertension.
62. SASTRY BK, NARASIMHAN C, REDDY NK, RAJU BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. (2004) 43(7):1149-1153. (Pubitemid 38452588)
63. GALIE N, MANES A, FARAHANI KV et al.: Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 14(9):713-717. (Pubitemid 41413297)
64. GHOFRANI HA, ROSE F, SCHERMULY RT et al.: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 42(1):158-164. •• Study assessing the clinical efficacy of sildenafil and inhaled iloprost combination.
65. KOTHARI SS, DUGGAL B: Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. (2002) 54(4):404-409. (Pubitemid 35447129)
66. MICHELAKIS ED, TYMCHAK W, NOGA M et al.: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 108(17):2066-2069. (Pubitemid 37337580)
67. MIKHAIL GW, PRASAD SK, LI W et al.: Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur. Heart J. (2004) 25(5):431-436. (Pubitemid 38391526)
68. SASTRY BK, NARASIMHAN C, REDDY NK et al.: A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. (2002) 54(4):410-414. (Pubitemid 35447130)
69. GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157. •• Randomised study examining the long term safety and efficacy of sildenafil, in PAH therapy.
70. MACHADO RF, MARTYR S, KATO GJ et al.: Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. (2005) 130(3):445-453. (Pubitemid 43899595)
71. HOEPER MM, FAULENBACH C, GOLPON H et al.: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. (2004) 24(6):1007-1010. (Pubitemid 39642293)
72. HOEPER MM, MARKEVYCH I, SPIEKERKOETTER E, WELTE T, NIEDERMEYER J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. (2005) 26(5):858-863. (Pubitemid 41632043)
73. HUMPL T, REYES JT, HOLTBY H, STEPHENS D, ADATIA I: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation (2005) 111(24):3274-3280. •• Study investigating the clinical efficacy of sildenafil in children with PAH. (Pubitemid 40875000)
74. KARATZA AA, BUSH A, MAGEE AG: Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int. J. Cardiol. (2005) 100(2):267-273. (Pubitemid 40502205)
75. LEE AJ, CHIAO TB, TSANG MP: Sildenafil for pulmonary hypertension. Ann. Pharmacother. (2005) 39(5):869-884.
76. BARST RJ: PDGF signaling in pulmonary arterial hypertension. J. Clin. Invest. (2005) 115(10):2691-2694. (Pubitemid 41434394)
77. http://www.pfizer.com/pfizer/download/uspi-viagra.pdf PFIZER, INC.: Viagra® (sildenafil citrate) prescribing information. Pfizer, Inc. NY, (NY) USA (2006). Accessed 3 August, 2006.
78. http://www.pfizer.com/pfizer/download/uspi-revatio.pdf PFIZER, INC.: Revatio® (sildenafil citrate) prescribing information. Pfizer, Inc. NY, (NY) USA (2006). Accessed 3 August, 2006.
79. http://clinicaltrials.gov/show/NCT00159913 A randomized, double-blind, placebo-controlled study of sildenafil in children with pulmonary arterial hypertension. Accessed 3 August, 2006.
80. http://clinicaltrials.gov/show/NCT00159874 Long term extension study evaluating safety of sildenafil citrate when used to treat PAH in children. Access 3 August, 2006.
81. http://clinicaltrials.gov/show/NCT00159887 Study to assess the longterm safety of sildenafil citrate in patients with pulmonary arterial hypertension. Accessed 3 August, 2006.